THE FINAL FRONTIER FOR eMTCT: ACUTE HIV INFECTION DURING...
Transcript of THE FINAL FRONTIER FOR eMTCT: ACUTE HIV INFECTION DURING...
![Page 1: THE FINAL FRONTIER FOR eMTCT: ACUTE HIV INFECTION DURING ...regist2.virology-education.com/2017/9HIVped/24_Drake.pdf · THE FINAL FRONTIER FOR eMTCT: ACUTE HIV INFECTION DURING AND](https://reader031.fdocuments.in/reader031/viewer/2022011803/5b7af66e7f8b9a184a8ba1a5/html5/thumbnails/1.jpg)
THE FINAL FRONTIER FOR eMTCT: ACUTE HIV INFECTION DURING AND AFTER PREGNANCY
Alison Drake, MPH, PhDUniversity of Washington
![Page 2: THE FINAL FRONTIER FOR eMTCT: ACUTE HIV INFECTION DURING ...regist2.virology-education.com/2017/9HIVped/24_Drake.pdf · THE FINAL FRONTIER FOR eMTCT: ACUTE HIV INFECTION DURING AND](https://reader031.fdocuments.in/reader031/viewer/2022011803/5b7af66e7f8b9a184a8ba1a5/html5/thumbnails/2.jpg)
I have nothing to disclose.
Disclosure
![Page 3: THE FINAL FRONTIER FOR eMTCT: ACUTE HIV INFECTION DURING ...regist2.virology-education.com/2017/9HIVped/24_Drake.pdf · THE FINAL FRONTIER FOR eMTCT: ACUTE HIV INFECTION DURING AND](https://reader031.fdocuments.in/reader031/viewer/2022011803/5b7af66e7f8b9a184a8ba1a5/html5/thumbnails/3.jpg)
Outline
3. Preventing MTCT
1. Primary prevention in women
Pre-exposure prophylaxis (PrEP) Safety and efficacy Eligibility Screening tools Innovative evaluations
Background on impact of acute maternal HIV on efforts to achieve eMTCT
Novel testing strategies When to test How to test
![Page 4: THE FINAL FRONTIER FOR eMTCT: ACUTE HIV INFECTION DURING ...regist2.virology-education.com/2017/9HIVped/24_Drake.pdf · THE FINAL FRONTIER FOR eMTCT: ACUTE HIV INFECTION DURING AND](https://reader031.fdocuments.in/reader031/viewer/2022011803/5b7af66e7f8b9a184a8ba1a5/html5/thumbnails/4.jpg)
Acute maternal infections contribute substantially to mother-to-child HIV transmission (MTCT)
UNAIDS Global Plan, 2016; Johnson LF, JAIDS 2012.
150,000New infections 2015
MTCT 2-23%UNAIDS 2015
50% MTCT2010-2015
46,000-69,00030 - 46%
MTCT attributed to acute maternal HIV
![Page 5: THE FINAL FRONTIER FOR eMTCT: ACUTE HIV INFECTION DURING ...regist2.virology-education.com/2017/9HIVped/24_Drake.pdf · THE FINAL FRONTIER FOR eMTCT: ACUTE HIV INFECTION DURING AND](https://reader031.fdocuments.in/reader031/viewer/2022011803/5b7af66e7f8b9a184a8ba1a5/html5/thumbnails/5.jpg)
Temporal shift in MTCT: Increasingly attributed to acute maternal HIV
Figure 2: Johnson LF, JAIDS 2012.
![Page 6: THE FINAL FRONTIER FOR eMTCT: ACUTE HIV INFECTION DURING ...regist2.virology-education.com/2017/9HIVped/24_Drake.pdf · THE FINAL FRONTIER FOR eMTCT: ACUTE HIV INFECTION DURING AND](https://reader031.fdocuments.in/reader031/viewer/2022011803/5b7af66e7f8b9a184a8ba1a5/html5/thumbnails/6.jpg)
MTCT: 22.7%
Higher MTCT rates attributed to incident infection in era of ART
Drake AL, PLoS Med 2014.
Low rates in chronic infection
![Page 7: THE FINAL FRONTIER FOR eMTCT: ACUTE HIV INFECTION DURING ...regist2.virology-education.com/2017/9HIVped/24_Drake.pdf · THE FINAL FRONTIER FOR eMTCT: ACUTE HIV INFECTION DURING AND](https://reader031.fdocuments.in/reader031/viewer/2022011803/5b7af66e7f8b9a184a8ba1a5/html5/thumbnails/7.jpg)
MTCT rates are underestimated due to acute maternal infections
CHRONIC
ACUTE & MISSED
33% 45%
Njuguna IN, AIDS Patient Care and STDs 2016.
78%
Attend ANC
HIV test
Pregnancy PostpartumPre-conception
+ =
![Page 8: THE FINAL FRONTIER FOR eMTCT: ACUTE HIV INFECTION DURING ...regist2.virology-education.com/2017/9HIVped/24_Drake.pdf · THE FINAL FRONTIER FOR eMTCT: ACUTE HIV INFECTION DURING AND](https://reader031.fdocuments.in/reader031/viewer/2022011803/5b7af66e7f8b9a184a8ba1a5/html5/thumbnails/8.jpg)
Contributions to MTCT due to acute infections are high, but relatively small proportion of mothers have new infections
Dinh TH,. PLOS ONE 2015; 10(5): e0125525.
South Africa 2011-2012
![Page 9: THE FINAL FRONTIER FOR eMTCT: ACUTE HIV INFECTION DURING ...regist2.virology-education.com/2017/9HIVped/24_Drake.pdf · THE FINAL FRONTIER FOR eMTCT: ACUTE HIV INFECTION DURING AND](https://reader031.fdocuments.in/reader031/viewer/2022011803/5b7af66e7f8b9a184a8ba1a5/html5/thumbnails/9.jpg)
Long cumulative duration for maternal HIV risk
Average life expectancy (yrs) 63
Total fertility rate (per woman)3.9
Years pregnant/lactating (per preg.)1.75
Total years pregnant/lactating6.8
= woman year
= pregnant/lactating
![Page 10: THE FINAL FRONTIER FOR eMTCT: ACUTE HIV INFECTION DURING ...regist2.virology-education.com/2017/9HIVped/24_Drake.pdf · THE FINAL FRONTIER FOR eMTCT: ACUTE HIV INFECTION DURING AND](https://reader031.fdocuments.in/reader031/viewer/2022011803/5b7af66e7f8b9a184a8ba1a5/html5/thumbnails/10.jpg)
High maternal HIV incidence rates
INCIDENCEAuthor, year Country Pregnancy Postpartum OverallKinuthia & Drake, 2015 Kenya 3.4 1.4 2.3De Schact, 2014 Mozambique 4.3Dinh, 2015 S. Africa 3.3%
Drake AL, PLoS Med 2014.
![Page 11: THE FINAL FRONTIER FOR eMTCT: ACUTE HIV INFECTION DURING ...regist2.virology-education.com/2017/9HIVped/24_Drake.pdf · THE FINAL FRONTIER FOR eMTCT: ACUTE HIV INFECTION DURING AND](https://reader031.fdocuments.in/reader031/viewer/2022011803/5b7af66e7f8b9a184a8ba1a5/html5/thumbnails/11.jpg)
Outline
3. Preventing MTCT Novel testing strategies
When to test How to test
Background on impact of acute maternal HIV on efforts to achieve eMTCT
Pre-exposure prophylaxis (PrEP) Safety and efficacy Eligibility Screening tools Innovative evaluations
![Page 12: THE FINAL FRONTIER FOR eMTCT: ACUTE HIV INFECTION DURING ...regist2.virology-education.com/2017/9HIVped/24_Drake.pdf · THE FINAL FRONTIER FOR eMTCT: ACUTE HIV INFECTION DURING AND](https://reader031.fdocuments.in/reader031/viewer/2022011803/5b7af66e7f8b9a184a8ba1a5/html5/thumbnails/12.jpg)
Guidance on timing of repeat testing lacks specificity
Labor
Pregnancy
3rd
trimester
Postpartum
Retesting criteria Concentrated epidemic
Generalized epidemic
3rd trimester, labor, or postpartum
Serodiscordant couple
Member of key population
![Page 13: THE FINAL FRONTIER FOR eMTCT: ACUTE HIV INFECTION DURING ...regist2.virology-education.com/2017/9HIVped/24_Drake.pdf · THE FINAL FRONTIER FOR eMTCT: ACUTE HIV INFECTION DURING AND](https://reader031.fdocuments.in/reader031/viewer/2022011803/5b7af66e7f8b9a184a8ba1a5/html5/thumbnails/13.jpg)
Country specific guidelines focus on retesting during late pregnancy and early postpartum
Delivery
Pregnancy
3rd
trimester
1st ANC
Postpartum
2, 6, 10, 14 weeks
6 months 9
months
![Page 14: THE FINAL FRONTIER FOR eMTCT: ACUTE HIV INFECTION DURING ...regist2.virology-education.com/2017/9HIVped/24_Drake.pdf · THE FINAL FRONTIER FOR eMTCT: ACUTE HIV INFECTION DURING AND](https://reader031.fdocuments.in/reader031/viewer/2022011803/5b7af66e7f8b9a184a8ba1a5/html5/thumbnails/14.jpg)
No clear “best” time to test based on prospective research
Delivery
Pregnancy Postpartum
3rd
trimester2, 6, 10, 14
weeks6
months 9 months
EnrollmentKinuthia & Drake, AIDS 2015.
![Page 15: THE FINAL FRONTIER FOR eMTCT: ACUTE HIV INFECTION DURING ...regist2.virology-education.com/2017/9HIVped/24_Drake.pdf · THE FINAL FRONTIER FOR eMTCT: ACUTE HIV INFECTION DURING AND](https://reader031.fdocuments.in/reader031/viewer/2022011803/5b7af66e7f8b9a184a8ba1a5/html5/thumbnails/15.jpg)
Long potential duration of breastfeeding warrants guidance on postnatal testing
Postnatal transmission (maternal seroconversion)
Antenatal transmission (maternal seroconversion)
Postnatal transmission (maternal chronic infection)
Antenatal transmission (maternal chronic infection)
Adapted from Figure 3b: Johnson LF, JAIDS 2012.
Acute infection: postnatal
transmission contributes
disproportionately to MTCT
![Page 16: THE FINAL FRONTIER FOR eMTCT: ACUTE HIV INFECTION DURING ...regist2.virology-education.com/2017/9HIVped/24_Drake.pdf · THE FINAL FRONTIER FOR eMTCT: ACUTE HIV INFECTION DURING AND](https://reader031.fdocuments.in/reader031/viewer/2022011803/5b7af66e7f8b9a184a8ba1a5/html5/thumbnails/16.jpg)
Timing of repeat testing will require balancing maternal and infant risks vs. benefits
Delivery
Pregnancy
3rd
trimester
1st ANC
Postpartum
2, 6, 10, 14 weeks
6 months 9
months
Late favors maternal benefit• detection• prevention
Early favors infant benefit• detection • prevention
![Page 17: THE FINAL FRONTIER FOR eMTCT: ACUTE HIV INFECTION DURING ...regist2.virology-education.com/2017/9HIVped/24_Drake.pdf · THE FINAL FRONTIER FOR eMTCT: ACUTE HIV INFECTION DURING AND](https://reader031.fdocuments.in/reader031/viewer/2022011803/5b7af66e7f8b9a184a8ba1a5/html5/thumbnails/17.jpg)
Implementation science approach to determining optimal timing of repeat testing
Delivery (n=930)
Pregnancy Postpartum
3rd trimester(n=930)
6 weeks (n=930)
6 months (n=930)
9 months (n=930)
NIH/NIAID K01 AI116298 (Drake, PI) Retest 4650 women
![Page 18: THE FINAL FRONTIER FOR eMTCT: ACUTE HIV INFECTION DURING ...regist2.virology-education.com/2017/9HIVped/24_Drake.pdf · THE FINAL FRONTIER FOR eMTCT: ACUTE HIV INFECTION DURING AND](https://reader031.fdocuments.in/reader031/viewer/2022011803/5b7af66e7f8b9a184a8ba1a5/html5/thumbnails/18.jpg)
Model parameters Country scenarios: Kenya, South Africa, Belarus, Cuba HIV prevalence / incidence Repeat testing: timing, guidelines, practices Behaviors: breastfeeding, condom use, ART initiation/
adherence Assays PrEP
Modeling impact and cost-effectiveness of repeat maternal testing for PMTCT
![Page 19: THE FINAL FRONTIER FOR eMTCT: ACUTE HIV INFECTION DURING ...regist2.virology-education.com/2017/9HIVped/24_Drake.pdf · THE FINAL FRONTIER FOR eMTCT: ACUTE HIV INFECTION DURING AND](https://reader031.fdocuments.in/reader031/viewer/2022011803/5b7af66e7f8b9a184a8ba1a5/html5/thumbnails/19.jpg)
Outline
3. Preventing MTCT Novel testing strategies
When to test How to test
Background on impact of acute maternal HIV on efforts to achieve eMTCT
Pre-exposure prophylaxis (PrEP) Safety and efficacy Eligibility Screening tools Innovative evaluations
![Page 20: THE FINAL FRONTIER FOR eMTCT: ACUTE HIV INFECTION DURING ...regist2.virology-education.com/2017/9HIVped/24_Drake.pdf · THE FINAL FRONTIER FOR eMTCT: ACUTE HIV INFECTION DURING AND](https://reader031.fdocuments.in/reader031/viewer/2022011803/5b7af66e7f8b9a184a8ba1a5/html5/thumbnails/20.jpg)
Barriers to repeat implementation of repeat testing
Rogers AJ, BMC Pregnancy and Childbirth 2016.
Individual
Late ANC presentation
Low ANC completion rates
Provider
Heavy workload
Time constraints
Difficulty checking repeat test eligibility
Facility
Inconsistent ANC volume
Lack of private space for testing
Alternative delivery systems may expand coverage and
reach
![Page 21: THE FINAL FRONTIER FOR eMTCT: ACUTE HIV INFECTION DURING ...regist2.virology-education.com/2017/9HIVped/24_Drake.pdf · THE FINAL FRONTIER FOR eMTCT: ACUTE HIV INFECTION DURING AND](https://reader031.fdocuments.in/reader031/viewer/2022011803/5b7af66e7f8b9a184a8ba1a5/html5/thumbnails/21.jpg)
What approaches are acceptable and feasible for repeat maternal testing?
Choose:Home, self test
ORClinic, blood test
Follow-up
Pregnancy Postpartum
3rd trimester OR 6 weeks 14 weeks1st ANC
RETEST
![Page 22: THE FINAL FRONTIER FOR eMTCT: ACUTE HIV INFECTION DURING ...regist2.virology-education.com/2017/9HIVped/24_Drake.pdf · THE FINAL FRONTIER FOR eMTCT: ACUTE HIV INFECTION DURING AND](https://reader031.fdocuments.in/reader031/viewer/2022011803/5b7af66e7f8b9a184a8ba1a5/html5/thumbnails/22.jpg)
Thirumurthy H, Lancet HIV 2016.
Peripartum women are willing to distribute self-tests to male partners
Half of women self-tested with their partner
![Page 23: THE FINAL FRONTIER FOR eMTCT: ACUTE HIV INFECTION DURING ...regist2.virology-education.com/2017/9HIVped/24_Drake.pdf · THE FINAL FRONTIER FOR eMTCT: ACUTE HIV INFECTION DURING AND](https://reader031.fdocuments.in/reader031/viewer/2022011803/5b7af66e7f8b9a184a8ba1a5/html5/thumbnails/23.jpg)
Kenya first country to nationally roll-out self-testing
Resources to support roll-out Hotline Website
![Page 24: THE FINAL FRONTIER FOR eMTCT: ACUTE HIV INFECTION DURING ...regist2.virology-education.com/2017/9HIVped/24_Drake.pdf · THE FINAL FRONTIER FOR eMTCT: ACUTE HIV INFECTION DURING AND](https://reader031.fdocuments.in/reader031/viewer/2022011803/5b7af66e7f8b9a184a8ba1a5/html5/thumbnails/24.jpg)
WHO endorses self-testing
![Page 25: THE FINAL FRONTIER FOR eMTCT: ACUTE HIV INFECTION DURING ...regist2.virology-education.com/2017/9HIVped/24_Drake.pdf · THE FINAL FRONTIER FOR eMTCT: ACUTE HIV INFECTION DURING AND](https://reader031.fdocuments.in/reader031/viewer/2022011803/5b7af66e7f8b9a184a8ba1a5/html5/thumbnails/25.jpg)
Delivery approaches in use for PMTCT Partner-
delivered
Service delivery approaches for self-testing
Integrated (reproductive
health)
PrEP
Facility (pick-up
/self-test)
Vending machines /
kiosks
Workplace
Adapted from Figure 2.5, 2016 WHO self-testing guidelines
Pharmacy
Community (door to
door)Internet
![Page 26: THE FINAL FRONTIER FOR eMTCT: ACUTE HIV INFECTION DURING ...regist2.virology-education.com/2017/9HIVped/24_Drake.pdf · THE FINAL FRONTIER FOR eMTCT: ACUTE HIV INFECTION DURING AND](https://reader031.fdocuments.in/reader031/viewer/2022011803/5b7af66e7f8b9a184a8ba1a5/html5/thumbnails/26.jpg)
Outline
1. Primary prevention in women
Pre-exposure prophylaxis (PrEP) Safety and efficacy Eligibility Screening tools Innovative evaluations
Background on impact of acute maternal HIV on efforts to achieve eMTCT
Novel testing strategies When to test How to test
![Page 27: THE FINAL FRONTIER FOR eMTCT: ACUTE HIV INFECTION DURING ...regist2.virology-education.com/2017/9HIVped/24_Drake.pdf · THE FINAL FRONTIER FOR eMTCT: ACUTE HIV INFECTION DURING AND](https://reader031.fdocuments.in/reader031/viewer/2022011803/5b7af66e7f8b9a184a8ba1a5/html5/thumbnails/27.jpg)
Safety data on tenofovir suggest PrEP is safe during pregnancy and lactation
![Page 28: THE FINAL FRONTIER FOR eMTCT: ACUTE HIV INFECTION DURING ...regist2.virology-education.com/2017/9HIVped/24_Drake.pdf · THE FINAL FRONTIER FOR eMTCT: ACUTE HIV INFECTION DURING AND](https://reader031.fdocuments.in/reader031/viewer/2022011803/5b7af66e7f8b9a184a8ba1a5/html5/thumbnails/28.jpg)
WHO technical brief on PrEP during pregnancy and breastfeeding
Population Additional considerations
Pre-conception for women:• Serodiscordant relationships• Unknown partner status• Partner unwilling to test
• “Bridge to partner viral suppression”
Adolescents•Requires additional supportfor information & adherence
•Consent may be barrier
Pregnant and postpartum women with substantial HIV risk
PrEP is safe and effective
![Page 29: THE FINAL FRONTIER FOR eMTCT: ACUTE HIV INFECTION DURING ...regist2.virology-education.com/2017/9HIVped/24_Drake.pdf · THE FINAL FRONTIER FOR eMTCT: ACUTE HIV INFECTION DURING AND](https://reader031.fdocuments.in/reader031/viewer/2022011803/5b7af66e7f8b9a184a8ba1a5/html5/thumbnails/29.jpg)
Outline
1. Primary prevention in women
Pre-exposure prophylaxis (PrEP) Safety and efficacy Eligibility Screening tools Innovative evaluations
Background on impact of acute maternal HIV on efforts to achieve eMTCT
Novel testing strategies When to test How to test
![Page 30: THE FINAL FRONTIER FOR eMTCT: ACUTE HIV INFECTION DURING ...regist2.virology-education.com/2017/9HIVped/24_Drake.pdf · THE FINAL FRONTIER FOR eMTCT: ACUTE HIV INFECTION DURING AND](https://reader031.fdocuments.in/reader031/viewer/2022011803/5b7af66e7f8b9a184a8ba1a5/html5/thumbnails/30.jpg)
PrEP implementation should maximize prevention while minimizing unnecessary exposure
Sero-discordance
Risk based
Universal (Opt-in)
Conservative
Anti-conservative
![Page 31: THE FINAL FRONTIER FOR eMTCT: ACUTE HIV INFECTION DURING ...regist2.virology-education.com/2017/9HIVped/24_Drake.pdf · THE FINAL FRONTIER FOR eMTCT: ACUTE HIV INFECTION DURING AND](https://reader031.fdocuments.in/reader031/viewer/2022011803/5b7af66e7f8b9a184a8ba1a5/html5/thumbnails/31.jpg)
Potential strategies to identify PrEP eligibility during pregnancy and lactation
100
2613
100
37 37
61
130
0
20
40
60
80
100
Universal HIV prevalence based Risk based
%
PrEP CoverageOffered PrEP (All)
Offered PrEP (high-risk)
Unnecessary
Universal HIV prevalence Risk
Pintye J, CROI 2017.
![Page 32: THE FINAL FRONTIER FOR eMTCT: ACUTE HIV INFECTION DURING ...regist2.virology-education.com/2017/9HIVped/24_Drake.pdf · THE FINAL FRONTIER FOR eMTCT: ACUTE HIV INFECTION DURING AND](https://reader031.fdocuments.in/reader031/viewer/2022011803/5b7af66e7f8b9a184a8ba1a5/html5/thumbnails/32.jpg)
Kenya well poised to evaluate PrEP during pregnancy and lactation
![Page 33: THE FINAL FRONTIER FOR eMTCT: ACUTE HIV INFECTION DURING ...regist2.virology-education.com/2017/9HIVped/24_Drake.pdf · THE FINAL FRONTIER FOR eMTCT: ACUTE HIV INFECTION DURING AND](https://reader031.fdocuments.in/reader031/viewer/2022011803/5b7af66e7f8b9a184a8ba1a5/html5/thumbnails/33.jpg)
Outline
1. Primary prevention in women
Pre-exposure prophylaxis (PrEP) Safety and efficacy Eligibility Screening tools Innovative evaluations
Background on impact of acute maternal HIV on efforts to achieve eMTCT
Novel testing strategies When to test How to test
![Page 34: THE FINAL FRONTIER FOR eMTCT: ACUTE HIV INFECTION DURING ...regist2.virology-education.com/2017/9HIVped/24_Drake.pdf · THE FINAL FRONTIER FOR eMTCT: ACUTE HIV INFECTION DURING AND](https://reader031.fdocuments.in/reader031/viewer/2022011803/5b7af66e7f8b9a184a8ba1a5/html5/thumbnails/34.jpg)
PrEP screening tools
Pintye J, CID 2017.
Rapid Assessment Screening Tool (RAST)
Partner• HIV status• Violence
Sex• Unprotected• Forced• Trade
STI
Post-exposure prophylaxis
Sharing needles
![Page 35: THE FINAL FRONTIER FOR eMTCT: ACUTE HIV INFECTION DURING ...regist2.virology-education.com/2017/9HIVped/24_Drake.pdf · THE FINAL FRONTIER FOR eMTCT: ACUTE HIV INFECTION DURING AND](https://reader031.fdocuments.in/reader031/viewer/2022011803/5b7af66e7f8b9a184a8ba1a5/html5/thumbnails/35.jpg)
Outline
1. Primary prevention in women
Pre-exposure prophylaxis (PrEP) Safety and efficacy Eligibility Screening tools Innovative evaluations
Background on impact of acute maternal HIV on efforts to achieve eMTCT
Novel testing strategies When to test How to test
![Page 36: THE FINAL FRONTIER FOR eMTCT: ACUTE HIV INFECTION DURING ...regist2.virology-education.com/2017/9HIVped/24_Drake.pdf · THE FINAL FRONTIER FOR eMTCT: ACUTE HIV INFECTION DURING AND](https://reader031.fdocuments.in/reader031/viewer/2022011803/5b7af66e7f8b9a184a8ba1a5/html5/thumbnails/36.jpg)
Ongoing evaluations testing approaches to PrEP delivery in Kenya
PrEP counseling guided by risk score in high prevalence
Universally offer
(including age 15-17)Offer PrEP based on partner self-test
PrEP counseling guided by risk score in high prevalence
Universally offer
Offer PrEP based on partner self-test
+ risk score
![Page 37: THE FINAL FRONTIER FOR eMTCT: ACUTE HIV INFECTION DURING ...regist2.virology-education.com/2017/9HIVped/24_Drake.pdf · THE FINAL FRONTIER FOR eMTCT: ACUTE HIV INFECTION DURING AND](https://reader031.fdocuments.in/reader031/viewer/2022011803/5b7af66e7f8b9a184a8ba1a5/html5/thumbnails/37.jpg)
Conclusions
3. Preventing MTCT
1. Primary prevention in women
Novel testing strategies can help, but need: Guidance on timing of retesting Evaluations of new delivery systems
Oral self-, partner, and home-based testing
Increasing need to focus upstream on PrEP Safe and effective to use Current projects will guide implementation
Acute maternal HIV contributes substantially to MTCT
![Page 38: THE FINAL FRONTIER FOR eMTCT: ACUTE HIV INFECTION DURING ...regist2.virology-education.com/2017/9HIVped/24_Drake.pdf · THE FINAL FRONTIER FOR eMTCT: ACUTE HIV INFECTION DURING AND](https://reader031.fdocuments.in/reader031/viewer/2022011803/5b7af66e7f8b9a184a8ba1a5/html5/thumbnails/38.jpg)
Future directions
3. Preventing MTCT
1. Primary prevention in women
Pre-exposure prophylaxis (PrEP) Counseling messages & tools Maternal adherence support Female controlled prevention
Acute maternal HIV contributes substantially to MTCT and must be addressed to achieve eMTCT
Novel testing strategies Counseling messages & tools Delivery systems & task-shifting Economic evaluations
4. Preventing unintended pregnancies
![Page 39: THE FINAL FRONTIER FOR eMTCT: ACUTE HIV INFECTION DURING ...regist2.virology-education.com/2017/9HIVped/24_Drake.pdf · THE FINAL FRONTIER FOR eMTCT: ACUTE HIV INFECTION DURING AND](https://reader031.fdocuments.in/reader031/viewer/2022011803/5b7af66e7f8b9a184a8ba1a5/html5/thumbnails/39.jpg)
2015Cuba
2016ArmeniaBelarusThailand
![Page 40: THE FINAL FRONTIER FOR eMTCT: ACUTE HIV INFECTION DURING ...regist2.virology-education.com/2017/9HIVped/24_Drake.pdf · THE FINAL FRONTIER FOR eMTCT: ACUTE HIV INFECTION DURING AND](https://reader031.fdocuments.in/reader031/viewer/2022011803/5b7af66e7f8b9a184a8ba1a5/html5/thumbnails/40.jpg)
Acknowledgements
Grace John-StewartKenneth SherrAnjuli Wagner David KatzRuanne BarnabasCarol LevinJillian PintyeShiza Farid
NIH/NIAID K01 AI116298UW CFAR NIA P30 AI27757Global Center for Integrated Health of Women, Adolescents, and Children (Global WACh)Kenya Research & Training Center (KRTC)World Health Organization (WHO)
John KinuthiaDaniel MatemoRuth NduatiPeter Cherutich